九安医疗
(002432)
| 流通市值：361.93亿 | | | 总市值：362.42亿 |
| 流通股本：4.64亿 | | | 总股本：4.65亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 301,482,711.39 | 1,365,588,936.68 | 1,069,311,569.11 | 765,265,184.21 |
| 营业收入 | 301,482,711.39 | 1,365,588,936.68 | 1,069,311,569.11 | 765,265,184.21 |
| 二、营业总成本 | 361,006,778.84 | 1,634,094,344.46 | 1,275,596,464.12 | 897,862,987.49 |
| 营业成本 | 93,463,056.11 | 493,971,286.09 | 369,995,524.32 | 258,813,949.77 |
| 税金及附加 | 438,649.67 | 2,648,251.55 | 1,968,240.06 | 1,505,858.83 |
| 销售费用 | 75,153,597.92 | 371,076,296.4 | 286,935,389.67 | 199,231,881.02 |
| 管理费用 | 79,629,481.64 | 474,635,281.11 | 400,638,725.18 | 293,967,905.08 |
| 研发费用 | 52,452,469.39 | 323,569,879.3 | 223,974,991.76 | 166,396,386.62 |
| 财务费用 | 59,869,524.11 | -31,806,649.99 | -7,916,406.87 | -22,052,993.83 |
| 其中:利息费用 | 29,746,463.51 | 113,523,735.72 | 87,661,109.27 | 54,527,455.57 |
| 其中:利息收入 | 23,625,138.61 | 139,086,039.26 | 109,731,439.07 | 75,555,419.19 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 300,155,063.44 | 2,113,542,831.27 | 1,251,365,123.94 | 733,616,951.84 |
| 加:投资收益 | 149,075,438.54 | 718,394,877.02 | 562,473,424.73 | 391,267,595.65 |
| 资产处置收益 | -37,605.41 | -8,487.15 | 1,044,484.58 | 949,866.31 |
| 资产减值损失(新) | -198,566.55 | -34,568,309.71 | -13,872,019.25 | -10,599,732.01 |
| 信用减值损失(新) | -928,430.22 | 2,763,905.92 | -2,330,146.47 | -3,598,921.77 |
| 其他收益 | 1,265,382.36 | 3,772,942.73 | 2,672,898.64 | 2,053,171.11 |
| 四、营业利润 | 389,807,214.71 | 2,535,392,352.3 | 1,595,068,871.16 | 981,091,127.85 |
| 加:营业外收入 | 1,357,069.58 | 6,526,135.48 | 1,874,420.48 | 462,806.95 |
| 减:营业外支出 | 5,303,277.87 | 14,659,638.21 | 636,145.43 | 509,942.05 |
| 五、利润总额 | 385,861,006.42 | 2,527,258,849.57 | 1,596,307,146.21 | 981,043,992.75 |
| 减:所得税费用 | 81,403,798.43 | 257,754,358.58 | 8,548,712.55 | 60,868,696.92 |
| 六、净利润 | 304,457,207.99 | 2,269,504,490.99 | 1,587,758,433.66 | 920,175,295.83 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 304,457,207.99 | 2,269,504,490.99 | 1,587,758,433.66 | 920,175,295.83 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 293,533,252.5 | 2,266,748,271.38 | 1,589,064,898.75 | 920,173,702.2 |
| 少数股东损益 | 10,923,955.49 | 2,756,219.61 | -1,306,465.09 | 1,593.63 |
| 扣除非经常损益后的净利润 | 345,084,121.26 | 2,292,144,672.33 | 1,577,970,459.76 | 880,819,463.65 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.7 | 5.23 | 3.66 | 2.1 |
| (二)稀释每股收益 | 0.7 | 5.21 | 3.64 | 2.1 |
| 八、其他综合收益 | -510,988,207.81 | -504,390,801.11 | 81,832,104.69 | 361,186,484.93 |
| 归属于母公司股东的其他综合收益 | -507,851,296.41 | -495,011,863.89 | 82,959,399.81 | 360,735,276.45 |
| 九、综合收益总额 | -206,530,999.82 | 1,765,113,689.88 | 1,669,590,538.35 | 1,281,361,780.76 |
| 归属于母公司股东的综合收益总额 | -214,318,043.91 | 1,771,736,407.49 | 1,672,024,298.56 | 1,280,908,978.65 |
| 归属于少数股东的综合收益总额 | 7,787,044.09 | -6,622,717.61 | -2,433,760.21 | 452,802.11 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-25 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |